Compound class:
Synthetic organic
Comment: Compound 13 is reported as a DOT1L inhibitor, with a novel chemical structure, distinct from that of pinometostat (EPZ-5676) [1]. Compound 13 acts as a SAM-competitive inhibitor, binding to an induced pocket adjacent to the SAM binding site.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Compound 13 exhibits a favourable selectivity profile against a panel of 22 PKMTs and PRMTs with no inhibitory activity up to 50μM [1]. It also suppress H3K79 dimethylation (IC50 16nM) and has a long on-target residence time as assessed by surface plasmon resonance experiments (> 240 minutes). In vitro, compound 13 effectively inhibits proliferation of the human MLL-rearranged leukemia cell line MV4-11 which expresses the oncogenic MLL-AF4 fusion . |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|